Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Investing Activities (2016 - 2025)

Ani Pharmaceuticals' Cash from Investing Activities history spans 16 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 86.86% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$34.3 million, up 91.52%, while the annual FY2025 figure was -$34.3 million, 91.52% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$1.4 million at Ani Pharmaceuticals, up from -$6.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $8.9 million in Q1 2024 and bottomed at -$398.5 million in Q3 2024.
  • The 5-year median for Cash from Investing Activities is -$4.7 million (2023), against an average of -$28.9 million.
  • The largest YoY upside for Cash from Investing Activities was 479.64% in 2024 against a maximum downside of 8652.95% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$82.2 million in 2021, then surged by 96.18% to -$3.1 million in 2022, then plummeted by 52.1% to -$4.8 million in 2023, then tumbled by 123.5% to -$10.7 million in 2024, then skyrocketed by 86.86% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Cash from Investing Activities are -$1.4 million (Q4 2025), -$6.2 million (Q3 2025), and -$6.9 million (Q2 2025).